A Phase 3 interventional study of SPM 962 and SPM 962 in Idiopathic Restless Legs Syndrome, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-06-05.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 10 in phase 3, and was the 9th registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2010.
This study's enrollment of 284 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 130 across the 19 interventional studies. Of the 19 that completed or were terminated, 13 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 3 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing rotigotine in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the clinical efficacy and safety of SPM962 in patients with restless legs syndrome (RLS) with once-daily repeated doses of 4.5mg and 6.75mg during a 13-week dose-titration and maintenance period. This is a multi-center, randomized, placebo-controlled, double-blind, 3-armed parallel group comparison study.
Efficacy will be determined by investigating the superiority of SPM962 to placebo in terms of the primary efficacy variable, change in International Restless Legs Syndrome Rating Scale (IRLS) total score from baseline to the end of the dose-maintenance period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who meet any of the following criteria relating to RLS treatment:
Exclusion Criteria:
Patients who have a serious abnormality at the screening test and at the baseline examination
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
started at 2.25 mg/day to 4.5 mg/day for 13 weeks
Drug: SPM 962
started at 2.25 mg/day to 6.75 mg/day for 13 weeks
Drug: SPM 962
for 13 weeks
Drug: Placebo of SPM 962
International Restless Legs Syndrome Rating Scale (IRLS) Total Score
Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Clinical Global Impression (CGI) Improvement
CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Patient Global Impression (PGI) Improvement
PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
The Pittsburgh Sleep Quality Index (PSQI)
Change of PSQI from baseline to the end of dose-titration/dose-maintenance period. PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Each Item of IRLS (10 Items)
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Incidence of RLS Symptoms
Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week\* 100%
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Average Duration of RLS Symptoms
Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
Incidence of RLS Symptoms in the Evening and Night
Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation \* 100%.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Average Duration of RLS Symptoms in the Evening and Night in a Week
Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
Nocturnal Awakenings Due to RLS Symptoms in a Week
Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation \* 100%.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (week 13)
Average Sleep Time in a Week
Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.
Time frame: Baseline, the end of dose-titration/dose-maintenance period (weeks 13)
| Milestone | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Started | 95 | 95 | 94 |
| Completed | 86 | 81 | 86 |
| Not completed | 9 | 14 | 8 |
| Withdrew: Adverse event | 2 | 9 | 4 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Protocol violation | 2 | 4 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 |
| Withdrew: Physician decision | 1 | 0 | 0 |
Change from the baseline to the end of dose-titration/dose-maintenance period. IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
| Scores on a scale | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| International Restless Legs Syndrome Rating Scale (IRLS) Total Score | -11.6 ± 8.2 | -14.3 ± 8.9 | -14.6 ± 9.0 |
CGI improvement is a clinician-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much improved, 2: much improved, 3: minimally improved, 4: no change, 5: minimally worse, 6: much worse, 7: very much worse.
| Percentage of Participants | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Subjects with "much improved" | 24.2 | 25.8 | 29.0 |
| Subjects with "very much improved" | 33.7 | 41.9 | 45.2 |
PGI improvement is a patient-reported scale for assessing how much the patient's illness has improved or worsened from baseline. The scale scoring criteria are 1: very much better, 2: much better, 3: a little better, 4: no change, 5: a little worse, 6: much worse, 7: very much worse.
| Percentage of Participants | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Subjects with "much improved" | 23.2 | 24.7 | 30.1 |
| Subjects with "very much improved" | 38.9 | 48.4 | 50.5 |
Change of PSQI from baseline to the end of dose-titration/dose-maintenance period. PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates "no difficulty" and 21 indicates "severe difficulty". A decrease in the scores means improvement.
| Scores on a scale | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| The Pittsburgh Sleep Quality Index (PSQI) | -2.5 ± 2.4 | -3.1 ± 3.2 | -3.2 ± 3.3 |
IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none). Numbers of subjects with -4 or -3 score change from baseline in each item of IRLS. A decrease in the scores means improvement.
| percentage of participants | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| -4 (RLS discomfort) | 1.1 | 2.2 | 6.4 |
| -3 (RLS discomfort) | 11.6 | 17.2 | 12.8 |
| -4 (need to move around due to RLS symptoms) | 2.1 | 2.2 | 7.4 |
| -3 (need to move around due to RLS symptoms) | 11.6 | 25.8 | 18.1 |
| -4 (discomfort relief by moving around) | 0 | 1.1 | 2.1 |
| -3 (discomfort relief by moving around) | 10.5 | 20.4 | 28.7 |
| -4 (severity of RLS as a whole) | 1.1 | 1.1 | 4.3 |
| -3 (severity of RLS as a whole) | 6.3 | 12.9 | 12.8 |
| -4 (RLS symptoms frequency) | 12.6 | 24.7 | 26.6 |
| -3 (RLS symptoms frequency) | 12.6 | 9.7 | 11.7 |
| -4 (average duration of RLS symptoms) | 1.1 | 2.2 | 2.1 |
| -3 (average duration of RLS symptoms) | 6.3 | 10.8 | 9.6 |
| -4 (severity of sleep disturbance) | 2.1 | 4.3 | 6.4 |
| -3 (severity of sleep disturbance) | 16.8 | 16.1 | 21.3 |
| -4 (tiredness or sleepiness during the day) | 0 | 2.2 | 2.1 |
| -3 (tiredness or sleepiness during the day) | 8.4 | 11.8 | 8.5 |
| -4 (severity of the impact on daily affairs) | 0 | 1.1 | 1.1 |
| -3 (severity of the impact on daily affairs) | 8.4 | 11.8 | 4.3 |
| -4 (severity of mood disturbance) | 1.1 | 4.3 | 1.1 |
| -3 (severity of mood disturbance) | 8.4 | 10.8 | 12.8 |
Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms in the week / the number of evaluation days in the week\* 100%
| percentage of days with RLS symptom | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Baseline | 85.7 ± 20.8 | 85.4 ± 20.5 | 83.2 ± 22.2 |
| Week 13 | 48.7 ± 40.9 | 35.8 ± 38.6 | 36.8 ± 38.8 |
Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.
| Hours | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Average Duration of RLS Symptoms | -3.1 ± 4.7 | -3.7 ± 4.6 | -4.3 ± 4.4 |
Incidence rate of RLS symptoms is calculated as the number of days with RLS symptoms / the number of days of evaluation \* 100%.
| percentage of days/week with symptoms | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Baseline | 80.6 ± 24.2 | 83.3 ± 20.8 | 79.5 ± 24.2 |
| Week 13 | 45.4 ± 41.0 | 34.6 ± 38.2 | 31.8 ± 37.7 |
Change of average duration of RLS symptoms in a week from baseline to the end of dose-titration/dose-maintenance period. Only the days with RLS symptoms are used for calculation.
| Hours | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Average Duration of RLS Symptoms in the Evening and Night in a Week | -1.3 ± 3.1 | -1.8 ± 2.5 | -1.5 ± 2.3 |
Nocturnal awakening rate is calculated as the number of days with nocturnal awakenings / the number of days of evaluation \* 100%.
| percentage of days/week with awakening | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Baseline | 33.5 ± 35.9 | 22.6 ± 31.3 | 28.3 ± 34.3 |
| Week 13 | 15.6 ± 31.7 | 7.7 ± 20.5 | 7.5 ± 19.5 |
Change of average sleep time in a week from baseline to the end of dose-titration/dose-maintenance period.
| Hours | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Average Sleep Time in a Week | 0.4 ± 0.8 | 0.5 ± 1.1 | 0.4 ± 1.1 |
Collected over 14 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/95 (2.1%) | 32/95 (33.7%) |
| SPM 962 4.5 | — | 0/95 (0%) | 72/95 (75.8%) |
| SPM 962 6.75 | — | 1/94 (1.1%) | 77/94 (81.9%) |
| Event | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| ContusionInjury, poisoning and procedural complications | 0/95 | 0/95 | 1/94 |
| Traffic AccidentInjury, poisoning and procedural complications | 0/95 | 0/95 | 1/94 |
| Lacunar InfarctionNervous system disorders | 1/95 | 0/95 | 0/94 |
| VIIth Nerve ParalysisNervous system disorders | 1/95 | 0/95 | 0/94 |
| Event | Placebo | SPM 962 4.5 | SPM 962 6.75 |
|---|---|---|---|
| Application Site ReactionGeneral disorders | 7/95 | 40/95 | 47/94 |
| NauseaGastrointestinal disorders | 9/95 | 32/95 | 41/94 |
| NasopharyngitisInfections and infestations | 12/95 | 12/95 | 16/94 |
| SomnolencePsychiatric disorders | 2/95 | 10/95 | 14/94 |
| VomitingGastrointestinal disorders | 1/95 | 4/95 | 10/94 |
| Abdominal DiscomfortGastrointestinal disorders | 3/95 | 0/95 | 10/94 |
| HeadacheNervous system disorders | 0/95 | 5/95 | 2/94 |
| Upper Respiratory Tract InflammationRespiratory, thoracic and mediastinal disorders | 1/95 | 3/95 | 4/94 |
| Ventricular ExtrasystolesCardiac disorders | 0/95 | 0/95 | 3/94 |
| ConstipationGastrointestinal disorders | 0/95 | 3/95 | 3/94 |
| Age, Continuous(years) | Placebo | SPM 962 4.5 | SPM 962 6.75 | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 15.3 | 50.7 ± 13.3 | 50.9 ± 13.7 | 51.7 ± 14.1 |
| Age, Categorical(Participants) | Placebo | SPM 962 4.5 | SPM 962 6.75 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 65 | 77 | 77 | 219 |
| >=65 years | 30 | 18 | 17 | 65 |
| Sex: Female, Male(Participants) | Placebo | SPM 962 4.5 | SPM 962 6.75 | Total |
|---|---|---|---|---|
| Female | 54 | 54 | 46 | 154 |
| Male | 41 | 41 | 48 | 130 |
| Region of Enrollment(participants) | Placebo | SPM 962 4.5 | SPM 962 6.75 | Total |
|---|---|---|---|---|
| Japan | 95 | 95 | 94 | 284 |
The record gives a start of Feb 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine
Otsuka Pharmaceutical Co., Ltd. →